ATE442164T1 - Quil a fraktion mit geringer toxizität und ihre verwendung - Google Patents

Quil a fraktion mit geringer toxizität und ihre verwendung

Info

Publication number
ATE442164T1
ATE442164T1 AT04749076T AT04749076T ATE442164T1 AT E442164 T1 ATE442164 T1 AT E442164T1 AT 04749076 T AT04749076 T AT 04749076T AT 04749076 T AT04749076 T AT 04749076T AT E442164 T1 ATE442164 T1 AT E442164T1
Authority
AT
Austria
Prior art keywords
quil
adjuvant
lps
derivatives
fractions
Prior art date
Application number
AT04749076T
Other languages
English (en)
Inventor
Bror Morein
Bengtsson Karin Livgren
Jill Ekstrim
Katarina Ranlund
Kefie Hu
Original Assignee
Isconova Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isconova Ab filed Critical Isconova Ab
Application granted granted Critical
Publication of ATE442164T1 publication Critical patent/ATE442164T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT04749076T 2003-07-07 2004-07-07 Quil a fraktion mit geringer toxizität und ihre verwendung ATE442164T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301998A SE0301998D0 (sv) 2003-07-07 2003-07-07 Quil A fraction with low toxicity and use thereof
PCT/SE2004/001038 WO2005002620A1 (en) 2003-07-07 2004-07-07 Quil a fraction with low toxicity and use thereof

Publications (1)

Publication Number Publication Date
ATE442164T1 true ATE442164T1 (de) 2009-09-15

Family

ID=27731119

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04749076T ATE442164T1 (de) 2003-07-07 2004-07-07 Quil a fraktion mit geringer toxizität und ihre verwendung

Country Status (15)

Country Link
US (8) US8821881B2 (de)
EP (1) EP1648505B1 (de)
JP (1) JP4731475B2 (de)
AT (1) ATE442164T1 (de)
AU (1) AU2004254152B2 (de)
BR (1) BRPI0412444B8 (de)
CA (1) CA2529363C (de)
DE (1) DE602004023089D1 (de)
DK (1) DK1648505T3 (de)
ES (1) ES2331952T3 (de)
NZ (1) NZ544299A (de)
PL (1) PL1648505T3 (de)
SE (1) SE0301998D0 (de)
WO (1) WO2005002620A1 (de)
ZA (1) ZA200600151B (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE315405T1 (de) * 1998-08-10 2006-02-15 Antigenics Inc Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
SE0202110D0 (sv) * 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) * 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
ES2433467T3 (es) 2005-01-20 2013-12-11 Isconova Ab Composición de vacuna que comprende una proteína de unión a fibronectina o un péptido de unión a fibronectina
EP1764369A1 (de) 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
AU2007231027B2 (en) 2006-03-24 2013-10-03 Novartis Influenza Vaccines Marburg Gmbh Storage of influenza vaccines without refrigeration
WO2008020335A2 (en) 2006-06-09 2008-02-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
EP1902727A1 (de) * 2006-09-22 2008-03-26 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
WO2008031878A1 (en) * 2006-09-15 2008-03-20 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH A composition for therapy and/or for prophylaxis of hbv-infections and hbv-mediated diseases
CN101563090B (zh) * 2006-11-20 2013-01-02 杜科姆公司 包含南美皂皮树皂苷的含脂质颗粒用于治疗癌症的用途
AU2008269439B2 (en) 2007-06-27 2013-12-19 Novartis Ag Low-additive influenza vaccines
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
HUE043493T2 (hu) 2008-06-27 2019-08-28 Zoetis Services Llc Új adjuváns készítmények
AU2010269148A1 (en) * 2009-07-10 2012-01-19 Isconova Ab New composition
CA2808556A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
DK2750683T4 (da) 2011-10-03 2021-04-12 Croda Int Plc Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser
JP6294828B2 (ja) 2011-11-28 2018-03-14 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． インフルエンザウイルスワクチンおよびその使用
NZ628385A (en) 2012-03-12 2016-09-30 Crucell Holland Bv Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
AP2014007994A0 (en) 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against rsv
US11576958B2 (en) 2013-02-07 2023-02-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
NZ630868A (en) 2013-03-08 2017-02-24 Janssen Vaccines & Prevention Bv Acellular pertussis vaccine
AR095962A1 (es) 2013-04-01 2015-11-25 Moreinx Ab Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
CA2910067C (en) 2013-04-25 2023-10-17 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
AU2014273173B2 (en) 2013-05-30 2018-09-27 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
KR102313153B1 (ko) 2013-06-17 2021-10-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
WO2015000832A1 (en) 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
US10806779B2 (en) 2013-07-02 2020-10-20 Janssen Vaccines & Prevention B.V. Method for preparing virosomes
CN109675029A (zh) 2013-09-19 2019-04-26 硕腾服务有限责任公司 油基佐剂
DE102014005771A1 (de) 2014-04-23 2015-10-29 Clariant International Ltd. Verwendung von wässrigen driftreduzierenden Zusammensetzungen
US10111944B2 (en) 2014-07-10 2018-10-30 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
MY181175A (en) 2014-11-04 2020-12-21 Janssen Vaccines & Prevention Bv Therapeutic hpv16 vaccines
KR102382773B1 (ko) 2015-01-16 2022-04-04 조에티스 서비시즈 엘엘씨 구제역 백신
CN107466324B (zh) 2015-04-14 2022-01-14 扬森疫苗与预防公司 具有双向启动子的表达两种转基因的重组腺病毒
BR112017027448A2 (pt) 2015-07-07 2018-09-04 Janssen Vaccines & Prevention Bv vacina contra rsv
CA2991540A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion respiratory syncytial sirus polypeptides
EA037295B1 (ru) 2015-08-20 2021-03-05 Янссен Вэксинс Энд Превеншн Б.В. Терапевтические вакцины против hpv18
EP4019044A3 (de) 2015-09-02 2022-08-24 Janssen Vaccines & Prevention B.V. Stabilisierte fusionsproteine der virusklasse i
CN114617959A (zh) 2015-09-03 2022-06-14 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
PE20181354A1 (es) 2015-12-23 2018-08-22 Pfizer Mutantes de proteina f de rsv
MY190320A (en) 2016-04-05 2022-04-13 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
KR102401247B1 (ko) 2016-04-05 2022-05-25 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
MX2018013340A (es) 2016-05-02 2019-08-21 Janssen Vaccines & Prevention Bv Combinaciones de vacunas terapeuticas para el vph.
DE202016003070U1 (de) 2016-05-09 2016-06-07 Clariant International Ltd. Stabilisatoren für Silikatfarben
RU2758238C2 (ru) 2016-05-12 2021-10-26 Янссен Вэксинс Энд Превеншн Б.В. Эффективный и сбалансированный двунаправленный промотор
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
CA3025441A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
RU2745500C2 (ru) 2016-06-20 2021-03-25 Янссен Вэксинс Энд Превеншн Б.В. Эффективный и сбалансированный двунаправленный промотор
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
JP6766260B2 (ja) 2016-11-04 2020-10-07 キャボット コーポレイションＣａｂｏｔ Ｃｏｒｐｏｒａｔｉｏｎ 結晶性ポリエステル及び有機シリカを含有するナノコンポジット
JP6721797B2 (ja) 2017-02-09 2020-07-15 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 異種遺伝子発現のための強力で短いプロモーター
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
US12083228B2 (en) 2017-07-24 2024-09-10 Novavax, Inc. Methods and compositions for treating respiratory disease
CN111163800A (zh) 2017-09-15 2020-05-15 扬森疫苗与预防公司 用于安全诱导针对rsv的免疫的方法
US11447526B2 (en) 2018-01-23 2022-09-20 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
MX2020009682A (es) 2018-03-19 2020-10-12 Novavax Inc Vacunas de nanoparticulas multivalentes contra la influenza.
GB201807303D0 (en) 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
WO2019224275A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
EP3880243A1 (de) 2018-11-13 2021-09-22 Janssen Vaccines & Prevention B.V. Stabilisierte präfusionierte rsv-f-proteine
MX2021012991A (es) 2019-04-25 2021-12-10 Janssen Vaccines & Prevention Bv Antigenos de gripe recombinantes.
BR112021022087A2 (pt) 2019-05-15 2021-12-28 Janssen Vaccines & Prevention Bv Coadministração de vacina sazonal contra influenza e vacina contra vírus respiratório sincicial à base de adenovírus
MX2021013947A (es) 2019-05-15 2021-12-14 Janssen Vaccines & Prevention Bv Tratamiento profilactico de la infeccion por virus sincitial respiratorio con una vacuna basada en adenovirus.
EP4025247A1 (de) 2019-09-05 2022-07-13 Janssen Vaccines & Prevention B.V. Influenzavirusimpfstoffe und verwendungen davon
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US20230075527A1 (en) 2020-01-31 2023-03-09 Janssen Pharmaceuticals, Inc Compositions and Methods for Preventing and Treating Coronavirus Infection - Sars-Cov-2 Vaccines
JP2023524860A (ja) 2020-05-11 2023-06-13 ヤンセン ファーマシューティカルズ，インコーポレーテッド ＳＡＲＳ－ＣｏＶ－２ワクチン
BR112022022942A2 (pt) 2020-05-11 2022-12-13 Janssen Pharmaceuticals Inc Réplicon de rna que codifica uma proteína spike de coronavírus estabilizada
BR112022022937A2 (pt) 2020-05-11 2022-12-20 Janssen Pharmaceuticals Inc Proteínas de fusão estabilizadas de proteína de pico de coronavírus
JP2023531554A (ja) 2020-06-29 2023-07-24 ヤンセン ファッシンズ アンド プリベンション ベーフェー 呼吸器合胞体ウイルス感染に対するワクチンの組み合わせ
IL299459A (en) 2020-07-06 2023-02-01 Janssen Pharmaceuticals Inc Proteins fused to stabilized coronavirus spike proteins
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
KR20230147156A (ko) 2021-02-19 2023-10-20 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합 전 rsv fb 항원
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN118234739A (zh) 2021-04-01 2024-06-21 扬森疫苗与预防公司 稳定的融合前piv3 f蛋白
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023110618A1 (en) 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2023196634A2 (en) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2023217988A1 (en) 2022-05-12 2023-11-16 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2024017682A1 (en) 2022-07-18 2024-01-25 Janssen Vaccines & Prevention B.V. Rsv immunogens
WO2024030856A2 (en) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Immunomodulatory proteins and related methods
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024061753A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
WO2024074584A1 (en) 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
WO2024104947A2 (en) 2022-11-14 2024-05-23 Janssen Vaccines & Prevention B.V. Influenza b virus vaccines and uses thereof
WO2024151583A2 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
US20240252614A1 (en) 2023-01-18 2024-08-01 Pfizer Inc. Vaccines against respiratory diseases
WO2024167885A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
WO2024175579A1 (en) 2023-02-21 2024-08-29 Janssen Vaccines & Prevention B.V. Stabilized trimeric rsv fusion proteins without a heterologous trimerzation domain

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5839376B2 (ja) * 1978-10-30 1983-08-30 富士通株式会社 イオン注入法
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
DE3775783D1 (de) * 1986-01-14 1992-02-20 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE9600647D0 (sv) * 1996-02-21 1996-02-21 Bror Morein Ny användning
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
SE0202110D0 (sv) * 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof

Also Published As

Publication number Publication date
PL1648505T3 (pl) 2010-02-26
JP4731475B2 (ja) 2011-07-27
US8821881B2 (en) 2014-09-02
ZA200600151B (en) 2007-01-31
CA2529363C (en) 2013-04-02
AU2004254152B2 (en) 2009-10-29
BRPI0412444B1 (pt) 2016-06-14
US20240024468A1 (en) 2024-01-25
WO2005002620A1 (en) 2005-01-13
US20200345840A1 (en) 2020-11-05
BRPI0412444B8 (pt) 2021-05-25
US20060239963A1 (en) 2006-10-26
ES2331952T3 (es) 2010-01-21
US20160184427A1 (en) 2016-06-30
NZ544299A (en) 2009-03-31
JP2007527386A (ja) 2007-09-27
US20150320858A1 (en) 2015-11-12
EP1648505B1 (de) 2009-09-09
SE0301998D0 (sv) 2003-07-07
DK1648505T3 (da) 2009-12-21
BRPI0412444A (pt) 2006-09-19
US20180369368A1 (en) 2018-12-27
AU2004254152A1 (en) 2005-01-13
DE602004023089D1 (de) 2009-10-22
US20140335049A1 (en) 2014-11-13
EP1648505A1 (de) 2006-04-26
US20220241408A1 (en) 2022-08-04
CA2529363A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
ATE442164T1 (de) Quil a fraktion mit geringer toxizität und ihre verwendung
MX360448B (es) Adyuvantes sinteticos de glucopiranosil-lipido.
MY137619A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
HUP0101564A2 (hu) Epotilon készítmények
WO2006120252A3 (en) Pyrido[2,3-d]pyrimidines useful as hcv inhibitors, and methods for the preparation thereof
WO2007109812A3 (en) Immunopotentiating compounds
WO2014205199A3 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
BR122018075729B8 (pt) flavivírus na preparação de uma composição de vacina
ECSP20046307A (es) Composiciones que comprenden microbiota coseleccionada y métodos para su uso
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
TW200407322A (en) Novel imidazopyridines as cyclin dependent kinase inhibitors
TW200745128A (en) Pyrazolopyrimidines as protein kinase inhibitors
MX2010001054A (es) Composiciones adyuvantes antigenicas y metodos.
WO2006031878A3 (en) Imidazoquinoline compounds
WO2008057512A3 (en) Imidazopyrazines as protein kinase inhibitors
UY27843A1 (es) Composicion de vacuna
AR044696A1 (es) Composicion de vacunas
BRPI0513288A (pt) uso de alcanóis fosfatados como dispersantes, emulsificantes, hodrótropos, agentes umectantes e agentes de compatabilidade em composições agriculturais
WO1996009805A3 (en) Chitosan induced immunopotentiation
SG10201901391RA (en) Induction of il-12 using immunotherapy
WO2006114680A3 (en) Vaccine adjuvants
WO2002053176A3 (en) An autologous anti-cancer vaccine
WO2006052841A3 (en) Glycolipids
FR2854631B1 (fr) Benzo-, naphto- et phenantrochromenes substitues en position 2 par un groupe arylamine et les compositions les renfermant
UY28047A1 (es) Derivados de 7h-dibenzo(b,g)(1,5)dioxocin-5-ona y su uso

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties